South San Francisco, CA, United States of America

Sunil R Bhonsle

This inventor holds 1 USPTO granted patent. Top assignee: Reacx Pharmaceuticals, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sunil R Bhonsle. Retrieved from https://idiyas.com/inventor/sunil-r-bhonsle-zlbd52ww

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sunil R. Bhonsle: Inventor in Implantable Drug Delivery

Introduction

Sunil R. Bhonsle is an inventor based in South San Francisco, California. His patent work includes an implantable drug delivery device designed to reduce the initial burst release of medication.

Latest Patents

Bhonsle is associated with 1 patent: “Implantable Devices for Drug Delivery with Reduced Burst Release.” The invention describes a device with a core made from a polymer or polymer blend containing one or more drugs or pharmaceutical substances, surrounded by an outer shell made from a polymer or polymer blend and one or more porogen materials. This design aims to reduce burst release. The device may deliver pharmaceuticals such as triiodothyronine (T3) or ropinirole.

Career Highlights

Bhonsle is associated with Reacx Pharmaceuticals, Inc. His patent work focuses on implantable systems for controlled pharmaceutical delivery.

Collaborations

His listed coworkers include Sunil Sreedharan and Rajesh A. Patel.

Conclusion

Sunil R. Bhonsle’s patent describes a polymer-based implantable drug delivery device intended to reduce burst release and support the delivery of pharmaceuticals such as T3 and ropinirole.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…